查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015149

神經調控市場：全球市場按應用、最終用戶、產品類型和技術分類的預測，2026-2032年

Neuromodulation Market by Application, End User, Product Type, Technology - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經調控市場價值將達到 66.1 億美元，到 2026 年將成長至 70.6 億美元，到 2032 年將達到 106.5 億美元，複合年成長率為 7.04%。

主要市場統計數據
基準年 2025 66.1億美元
預計年份：2026年 70.6億美元
預測年份 2032 106.5億美元
複合年成長率 (%) 7.04%

清楚概述了技術進步、不斷發展的護理路徑和支付方的優先事項如何重新定義神經調控的臨床實施和策略規劃。

神經調控正從一種小眾治療性介入轉變為涵蓋疼痛、神經系統疾病和功能障礙等多面向診療路徑的核心組成部分。設備小型化、封閉回路型感測和非侵入性給藥技術的最新進展正在重塑臨床決策，擴大可從治療中獲益的患者群體，並再形成治療的醫療環境。同時，不斷變化的健保報銷政策和日益成長的看護者期望也在改變製造商、醫療服務提供者和支付方評估治療價值和風險的方式。

快速的技術整合、不斷擴大的適應症以及以生態系統為中心的經營模式正在重塑神經調控策略和患者照護服務。

在神經調控領域，技術、臨床和市場因素的融合正在帶來變革性的轉變。感測和刺激技術的進步，特別是封閉回路型脊髓系統的進步，使人們對設備不僅能夠提供治療，還能即時適應生理訊號的期望日益提高。同時，非侵入性治療方法的進步正在將治療範圍擴展到門診和家庭環境，使更多患者能夠接受治療，同時也改變了醫療服務提供者的工作流程和培訓要求。

對美國關稅政策變化對神經調控供應鏈、採購行為和策略商業化選擇的多方面影響進行評估。

美國關稅的變化對神經調控供應鏈、採購流程和策略採購產生了多方面的影響。零件和進口子系統關稅的提高推高了依賴全球生產網路的製造商的單位成本，促使他們重新設計供應鏈並考慮近岸外包。為此，各公司正在重新評估與供應商的關係，並加快關鍵製造活動的在地化進程，以降低貿易政策變化帶來的風險。

詳細的細分觀點揭示了產品子類型、治療應用、醫療保健環境和技術方法如何結合起來，從而決定部署管道和商業化優先事項。

透過嚴謹的市場區隔觀點了解市場，對於制定精準的策略和產品定位至關重要。按產品類型分析，市場涵蓋深部腦部刺激 (DBS)、薦椎神經刺激)、脊髓刺激 (SPS)、經皮電神經刺激 (ECT) 和迷走神經刺激 (VAS)，這些顯著的產品細分影響著臨床效用和商業性吸引力。深部腦刺激 (DBS) 設備以定向導線和環形導線架構為特徵，每種架構在標靶精度和植入複雜性之間各有優劣。薦椎神經刺激(SNS) 設備分為不可充電系統和可充電系統，這影響著關於患者追蹤頻率和總治療成本的討論。在脊髓刺激方面，與開放回路法相比，基於生理回饋調節刺激的封閉回路型系統在療效和病人滿意度方面具有明顯的價值提案。經皮電神經刺激 (ECT) 包括攜帶式和固定式設備，這影響其在門診和家庭環境中的應用趨勢。迷走神經刺激療法進一步分為植入式和非侵入式兩種類型，每種類型都有不同的風險接受度和臨床適應症。

美洲、歐洲、中東和非洲以及亞太地區在促進市場准入的因素方面存在區域趨勢和差異，這些因素決定了臨床引入和商業策略的實施。

區域趨勢影響臨床應用和商業策略，不同區域的促進因素各不相同。在美洲，先進的臨床中心集中分佈，法規環境有利於醫療設備認證，以及對基於療效的報銷模式日益成長的興趣，都在加速高複雜度神經調控系統的應用，這些系統在臨床實踐中表現出卓越的性能。醫療服務向門診和家庭環境的轉變尤為顯著，促使製造商投資研發攜帶式和方便用戶使用的解決方案。

成熟企業、Start-Ups和跨產業夥伴關係如何透過平台創新、實證策略和綜合服務模式來競爭，以引領神經調控市場。

神經調控領域的競爭動態呈現出成熟領導者、新興挑戰者以及跨產業合作並存的態勢，這些合作將醫療設備專業知識與軟體和服務結合。成熟的醫療設備製造商持續投資於平台的漸進式改進，同時選擇性地進行收購，以拓展其治療產品組合併增強服務能力。同時，Start-Ups的新創公司則專注於小眾臨床適應症、新型給藥方法和差異化的使用者體驗，並經常利用數位療法和遠端監測來延長臨床價值鏈。

製造商和醫療保健系統領導者面臨的實際策略挑戰是，透過協調創新、證據、供應鏈韌性和支付方參與來加速採用。

產業領導者應採取多管齊下的策略，將產品創新與切實可行的臨床應用路徑和支付方的認可相結合。優先投資閉合迴路感測和演算法主導的治療最佳化技術能夠帶來顯著的臨床差異化優勢，但這些技術優勢必須與全面的真實世界證據（REW）計畫相結合，以證明其長期療效和成本效益。同時，企業應設計模組化的經營模式，既支持醫院的融資管道，也支持門診和居家照護機構的訂閱或療效導向模式。

一個透明的多方法研究框架，結合臨床醫生訪談、監管分析和數據三角測量，以檢驗產品和護理各個方面的見解。

本研究整合了多種調查方法，旨在對神經調控的現狀形成穩健且檢驗的認知。主要研究包括對臨床醫生、醫院採購經理、保險公司、醫療設備研發主管和供應鏈專家進行結構化訪談，以了解他們對臨床工作流程、應用障礙和商業化重點的實際觀點。次要研究則利用同儕審查的臨床文獻、監管申報文件、技術規範和公共文件，檢驗了技術特性和監管路徑。

對不斷發展的神經調控領域進行簡要概述，重點強調技術整合、證據優先排序和適應性商業化是長期領先地位的決定因素。

總而言之，神經調控正處於一個轉折點，技術成熟、臨床適應症不斷擴大以及支付方期望不斷變化，三者交匯融合，既帶來了重要的戰略機遇，也帶來了運營挑戰。能夠將先進的感測技術和自適應刺激與嚴謹的真實世界證據、以臨床醫生為中心的培訓以及穩健的供應鏈相結合的機構，將獲得成功。同樣重要的是，機構還需具備建構以報銷為導向的價值主張的能力，將臨床結果轉化為可衡量的系統級效益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：神經調控市場：依應用領域分類

  • 慢性疼痛的管理
  • 憂鬱症
  • 癲癇
  • 運動障礙
  • 尿失禁

第9章：神經調控市場：依最終用戶分類

  • 門診手術中心
  • 居家照護
  • 醫院

第10章：神經調控市場：依產品類型分類

  • 深部腦部刺激
    • 定向
    • 戒指
  • 薦椎神經刺激
    • 不可充電
    • 可充電的
  • 脊髓刺激療法
    • 封閉回路型
    • 開放回路
  • 經皮電神經刺激
    • 攜帶式的
    • 固定式
  • 迷走神經刺激
    • 嵌入式
    • 非侵入性

第11章 神經調控市場：依技術分類

  • 侵入性
  • 非侵入性

第12章 神經調控市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：神經調控市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 神經調控市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國神經調控市場

第16章：中國神經調控市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Axonics Modulation Technologies, Inc.
  • Boston Scientific Corporation
  • ElectroCore, Inc.
  • Helius Medical Technologies, Inc.
  • LivaNova PLC
  • Medtronic plc
  • MicroTransponder, Inc.
  • Neuronetics, Inc.
  • Nevro Corporation
  • Nuvectra Corporation
  • Zynex Medical, Inc.
Product Code: MRR-036C5CF3B4DB

The Neuromodulation Market was valued at USD 6.61 billion in 2025 and is projected to grow to USD 7.06 billion in 2026, with a CAGR of 7.04%, reaching USD 10.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.61 billion
Estimated Year [2026] USD 7.06 billion
Forecast Year [2032] USD 10.65 billion
CAGR (%) 7.04%

An incisive overview of how technological advances, care pathway evolution, and payer priorities are redefining clinical adoption and strategic planning in neuromodulation

Neuromodulation is moving from niche therapeutic interventions to a core component of multimodal care pathways across pain, neurological, and functional disorders. Recent advances in device miniaturization, closed-loop sensing, and noninvasive delivery have reconfigured clinical decision-making, broadening the pool of patients who can benefit while reshaping the care settings in which therapies are delivered. At the same time, shifting reimbursement priorities and evolving caregiver expectations are altering how manufacturers, providers, and payers assess value and risk.

This landscape demands an integrated perspective that couples clinical efficacy with system-level feasibility. Emerging partnerships between device companies and software developers are accelerating pathway optimization, while heightened scrutiny on long-term outcomes is prompting operators to invest in post-market evidence generation. Consequently, strategic plans must reconcile product roadmaps with real-world adoption barriers and opportunities, aligning regulatory strategy, clinical trial design, and commercial execution to the realities of contemporary healthcare delivery.

Transitioning from technology promise to sustained clinical impact requires stakeholders to focus on interoperability, patient experience, and health economics. Institutions that anticipate these converging imperatives will be better positioned to lead adoption, influence reimbursement decision-makers, and extract long-term value from neuromodulation innovations.

How rapid technology integration, expanding therapeutic indications, and ecosystem-focused commercial models are reshaping neuromodulation strategy and patient care delivery

The neuromodulation landscape is experiencing transformative shifts driven by converging technological, clinical, and market forces. Advances in sensing and stimulation, particularly closed-loop spinal cord systems, are elevating the expectation that devices will not only deliver therapy but also adapt in real time to physiologic signals. Parallel progress in noninvasive modalities is expanding therapeutic reach into outpatient and home settings, enabling broader patient access while changing provider workflows and training requirements.

Clinical paradigms are also shifting as neuromodulation indications diversify beyond chronic pain to include mood disorders, epilepsy, and functional urology. This expansion creates new demand for differentiated clinical evidence and specific outcome measures that resonate with both clinicians and payers. Interoperability between stimulation platforms and digital health ecosystems is emerging as a competitive differentiator, with integrated data capture enabling outcomes-based contracting and more precise therapy titration.

From a commercial perspective, competitive dynamics are moving toward strategic partnerships and ecosystem plays rather than single-product competition. Device manufacturers are increasingly collaborating with software vendors, contract research organizations, and health systems to co-develop care pathway solutions that reduce friction in adoption. These shifts necessitate an adaptive strategy that emphasizes lifecycle evidence generation, scalable training models, and flexible reimbursement frameworks.

Assessing the multifaceted consequences of shifting tariff policies on neuromodulation supply chains, procurement behavior, and strategic commercialization choices in the United States

Tariff changes in the United States are exerting a multifaceted influence on neuromodulation supply chains, procurement behavior, and strategic sourcing. Increased duties on components and imported subsystems are elevating unit costs for manufacturers that rely on globalized production networks, prompting supply chain redesigns and nearshoring considerations. In response, companies are re-evaluating supplier relationships and accelerating localization of key manufacturing activities to mitigate exposure to trade policy volatility.

Procurement teams within hospitals and ambulatory centers are reacting to cost pressures by intensifying value negotiations and prioritizing capital allocation toward devices that demonstrate durable clinical benefit and clear total cost of care advantages. Simultaneously, manufacturers are recalibrating pricing strategies and exploring cost-containment innovations in device design and packaging. These adaptations are also influencing the timing and scope of new product introductions, as firms weigh the benefits of launching in tariff-impacted markets against potential margin compression.

Beyond immediate cost implications, tariff shifts are modifying strategic planning around clinical trials and post-market surveillance. Companies conducting multinational studies must account for expanded logistics costs and potential delays in device availability. Consequently, stakeholders that proactively redesign supply chains, invest in flexible manufacturing, and strengthen contractual protections with suppliers are better positioned to sustain operations and preserve competitive momentum under evolving trade regimes.

Detailed segmentation perspective revealing how product subtypes, therapeutic applications, care settings, and technology approaches together define adoption pathways and commercialization priorities

Understanding the market through a rigorous segmentation lens is essential for precise strategy formulation and product positioning. When analyzed by product type, the market spans Deep Brain Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation, and Vagus Nerve Stimulation, with meaningful product sub-distinctions that influence clinical utility and commercial appeal. Deep Brain Stimulation devices are differentiated by directional and ring lead architectures, each offering trade-offs between targeting precision and implant complexity. Sacral Nerve Stimulation options bifurcate into nonrechargeable and rechargeable systems, affecting patient follow-up cadence and total cost of care discussions. Within Spinal Cord Stimulation, closed-loop systems that adjust stimulation based on physiologic feedback contrast with open-loop paradigms, creating distinct value propositions around efficacy and patient satisfaction. Transcutaneous Electrical Nerve Stimulation is available in portable and stationary formats, which drives adoption dynamics across ambulatory and home environments. Vagus Nerve Stimulation further divides into implanted and noninvasive variants, each aligning differently with procedural risk tolerance and clinical indications.

Application-based segmentation highlights where clinical need and reimbursement alignment intersect. Chronic pain management remains a dominant clinical target, while depression, epilepsy, movement disorders, and urinary incontinence represent expanding therapeutic corridors that require tailored evidence packages and specialist engagement. End-user segmentation clarifies adoption contexts; ambulatory surgical centers, home care, and hospitals present divergent procurement cycles, clinician skill sets, and operational constraints that inform go-to-market tactics. Finally, technology-based segmentation into invasive and noninvasive modalities underscores distinct regulatory pathways, safety profiles, and patient acceptance challenges. Synthesizing these segmentation dimensions reveals where product innovation, clinical evidence, and commercialization resources should be concentrated to achieve rapid adoption and durable uptake.

Regional dynamics and differentiated access drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine clinical uptake and commercial strategy execution

Regional dynamics shape both clinical adoption and commercial strategy, with distinct drivers unfolding across major geographies. In the Americas, a concentration of advanced clinical centers, a favorable regulatory environment for iterative device approvals, and growing interest in outcomes-based reimbursement combine to accelerate uptake of high-complexity neuromodulation systems that demonstrate robust real-world performance. Transitioning care into outpatient and home settings is especially pronounced, prompting manufacturers to invest in portable and user-friendly solutions.

Across Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable reimbursement policies create a patchwork of access pathways. High-income European healthcare systems are focused on comparative effectiveness and long-term cost offsets, driving demand for rigorous registry data and head-to-head evidence. Markets in the Middle East and Africa are characterized by selective early-adopter centers and investment in tertiary capabilities, with opportunities tied to regional center-of-excellence models and medical tourism strategies. These contrasts require tailored market entry plans that align clinical evidence generation with local payer expectations.

Asia-Pacific exhibits rapid innovation adoption in select urban centers, supported by expanding private healthcare networks and a growing base of patients seeking advanced neuromodulation therapies. Regulatory modernization and investments in domestic manufacturing are altering competitive dynamics, while diverse healthcare funding models-from public reimbursement to out-of-pocket payments-shape pricing and access strategies. Together, these regional variations demand nuanced commercial playbooks that respect local clinical practice patterns, reimbursement mechanisms, and supply chain realities.

How incumbents, startups, and cross-sector partnerships are competing through platform innovation, evidence strategies, and integrated service models to lead neuromodulation markets

Competitive dynamics in neuromodulation are characterized by an interplay of incumbent leadership, emerging challengers, and cross-sector partnerships that combine device expertise with software and services. Established device manufacturers continue to invest in incremental platform improvements while selectively pursuing acquisitions to broaden therapy portfolios and strengthen service capabilities. At the same time, agile startups are focusing on niche clinical indications, novel delivery modalities, and differentiated user experiences, often leveraging digital therapeutics and remote monitoring to extend the clinical value chain.

Strategic partnerships between device firms and technology companies are accelerating the integration of closed-loop sensing, cloud-based outcomes analytics, and patient engagement tools. Such collaborations help address one of the market's central needs: converting discrete device performance into measurable improvements across care pathways. Contract manufacturers and specialized component suppliers are also assuming greater strategic importance as firms optimize production flexibility in response to supply chain pressures.

Beyond product competition, firms are differentiating through evidence strategies, training and support ecosystems for clinicians, and creative contracting with payers to share performance risk. Companies that align these capabilities-innovative devices, robust clinical data, scalable clinician training, and payer-aligned value propositions-are the most likely to sustain competitive advantage in this evolving market.

Practical strategic imperatives for manufacturers and health system leaders that align innovation, evidence, supply chain resilience, and payer engagement to accelerate adoption

Industry leaders should adopt a multi-dimensional approach that links product innovation with practical pathways for clinical adoption and payer acceptance. Prioritizing investment in closed-loop sensing and algorithm-driven therapy optimization will create clear clinical differentiation, but these technical advantages must be paired with comprehensive real-world evidence programs that demonstrate longitudinal outcomes and cost offsets. In parallel, companies should design modular business models that support both capital acquisition channels for hospitals and subscription or outcome-based models for ambulatory and home care settings.

Operationally, strengthening supplier diversification and near-term localization options will mitigate trade policy risk and support faster time-to-market. Companies should also accelerate clinician training by deploying scalable simulation and digital learning platforms that reduce the friction of adoption and shorten the time to optimal therapy titration. From a market access perspective, early engagement with payers and health technology assessment bodies to co-develop outcome metrics and registries will smooth reimbursement pathways and support differentiated contracting.

Finally, pursuing selective partnerships with digital health firms and specialized service providers can extend the therapeutic value proposition beyond the implant, enabling remote monitoring, adherence support, and post-market evidence collection. This integrated approach will translate device innovation into measurable improvements in patient outcomes and provider efficiency, strengthening long-term market positioning.

A transparent multi-method research framework combining clinician interviews, regulatory analysis, and data triangulation to validate insights across product and care dimensions

This research synthesizes multiple methodological strands to produce a robust, validated view of the neuromodulation landscape. Primary research consisted of structured interviews with clinicians, hospital procurement leads, payers, device development executives, and supply chain specialists to capture frontline perspectives on clinical workflows, adoption barriers, and commercialization priorities. Secondary research leveraged peer-reviewed clinical literature, regulatory filings, technical specifications, and public policy documents to validate technical characteristics and regulatory pathways.

Data triangulation combined qualitative insights with device technology reviews and commercial activity mapping to ensure consistency across inputs. The analytical framework segmented the market by product type, application, end user, and technology modality, enabling a granular examination of demand drivers and adoption contexts. Key assumptions and sources were cross-checked with domain experts and supplemented by advisory board reviews to enhance validity and relevance.

Limitations were acknowledged where publicly available data are constrained, and sensitivity analyses were applied to test alternative scenarios. Ethical standards and confidentiality protocols governed primary interviews, and care was taken to anonymize proprietary information. This multi-method approach provides a defensible foundation for strategic decision-making while preserving transparency about methodology and evidence sources.

A concise synthesis of the evolving neuromodulation environment emphasizing technology integration, evidence priorities, and adaptive commercialization as determinants of long-term leadership

In summation, neuromodulation is at an inflection point where technological maturation, expanding clinical indications, and evolving payer expectations converge to create significant strategic opportunities and operational challenges. Success will favor organizations that can integrate advanced sensing and adaptive stimulation with rigorous real-world evidence, clinician-centric training, and resilient supply chains. Equally important is the ability to craft reimbursement-focused value narratives that translate clinical outcomes into measurable system-level benefits.

As stakeholders navigate tariff volatility and regional access heterogeneity, adaptive commercial strategies that blend global scale with local execution will be essential. Firms that proactively cultivate partnerships across software, services, and clinical networks will be positioned to convert device innovation into meaningful improvements in patient care and financial performance. Ultimately, a disciplined focus on evidence generation, interoperability, and patient experience will determine which players achieve sustained leadership in the evolving neuromodulation ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuromodulation Market, by Application

  • 8.1. Chronic Pain Management
  • 8.2. Depression
  • 8.3. Epilepsy
  • 8.4. Movement Disorders
  • 8.5. Urinary Incontinence

9. Neuromodulation Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Home Care
  • 9.3. Hospitals

10. Neuromodulation Market, by Product Type

  • 10.1. Deep Brain Stimulation
    • 10.1.1. Directional
    • 10.1.2. Ring
  • 10.2. Sacral Nerve Stimulation
    • 10.2.1. Nonrechargeable
    • 10.2.2. Rechargeable
  • 10.3. Spinal Cord Stimulation
    • 10.3.1. Closed Loop
    • 10.3.2. Open Loop
  • 10.4. Transcutaneous Electrical Nerve Stimulation
    • 10.4.1. Portable
    • 10.4.2. Stationary
  • 10.5. Vagus Nerve Stimulation
    • 10.5.1. Implanted
    • 10.5.2. Noninvasive

11. Neuromodulation Market, by Technology

  • 11.1. Invasive
  • 11.2. Noninvasive

12. Neuromodulation Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neuromodulation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neuromodulation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Neuromodulation Market

16. China Neuromodulation Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Axonics Modulation Technologies, Inc.
  • 17.7. Boston Scientific Corporation
  • 17.8. ElectroCore, Inc.
  • 17.9. Helius Medical Technologies, Inc.
  • 17.10. LivaNova PLC
  • 17.11. Medtronic plc
  • 17.12. MicroTransponder, Inc.
  • 17.13. Neuronetics, Inc.
  • 17.14. Nevro Corporation
  • 17.15. Nuvectra Corporation
  • 17.16. Zynex Medical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROMODULATION MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROMODULATION MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROMODULATION MARKET SIZE, BY MOVEMENT DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROMODULATION MARKET SIZE, BY MOVEMENT DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROMODULATION MARKET SIZE, BY MOVEMENT DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY INCONTINENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY INCONTINENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY INCONTINENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROMODULATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROMODULATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROMODULATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROMODULATION MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROMODULATION MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROMODULATION MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROMODULATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROMODULATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROMODULATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROMODULATION MARKET SIZE, BY DIRECTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROMODULATION MARKET SIZE, BY DIRECTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROMODULATION MARKET SIZE, BY DIRECTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROMODULATION MARKET SIZE, BY RING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROMODULATION MARKET SIZE, BY RING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROMODULATION MARKET SIZE, BY RING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROMODULATION MARKET SIZE, BY NONRECHARGEABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROMODULATION MARKET SIZE, BY NONRECHARGEABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROMODULATION MARKET SIZE, BY NONRECHARGEABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROMODULATION MARKET SIZE, BY RECHARGEABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROMODULATION MARKET SIZE, BY RECHARGEABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROMODULATION MARKET SIZE, BY RECHARGEABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROMODULATION MARKET SIZE, BY CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROMODULATION MARKET SIZE, BY CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROMODULATION MARKET SIZE, BY CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROMODULATION MARKET SIZE, BY OPEN LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROMODULATION MARKET SIZE, BY OPEN LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROMODULATION MARKET SIZE, BY OPEN LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROMODULATION MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROMODULATION MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROMODULATION MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROMODULATION MARKET SIZE, BY STATIONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROMODULATION MARKET SIZE, BY STATIONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROMODULATION MARKET SIZE, BY STATIONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROMODULATION MARKET SIZE, BY IMPLANTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROMODULATION MARKET SIZE, BY IMPLANTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROMODULATION MARKET SIZE, BY IMPLANTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROMODULATION MARKET SIZE, BY NONINVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROMODULATION MARKET SIZE, BY NONINVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROMODULATION MARKET SIZE, BY NONINVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROMODULATION MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROMODULATION MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROMODULATION MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROMODULATION MARKET SIZE, BY NONINVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROMODULATION MARKET SIZE, BY NONINVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROMODULATION MARKET SIZE, BY NONINVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS NEUROMODULATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. G7 NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. NATO NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. NATO NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)